← Back to Screener
AEON Biopharma, Inc. (AEON)
Price$0.72
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-22.72%
Price vs S&P 500 (4W)-19.80%
VGM Score40.66
Market Capitalization$18.99M
P/E Ratio (Annual)0.54x
All Metrics
Book Value / Share (Quarterly)$1.09
P/TBV (Annual)0.74x
Cash Flow / Share (Quarterly)$-0.48
Price vs S&P 500 (YTD)-42.55%
EPS (TTM)$-4.16
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-4.16
EPS (Annual)$-3.95
ROI (Annual)2.31%
Cash / Share (Quarterly)$0.25
P/E Normalized (Annual)0.54x
ROA (Last FY)-705.43%
EBITD / Share (TTM)$-0.96
Cash Flow / Share (Annual)$-1.43
P/B Ratio (Quarterly)4.90x
Net Income / Employee (Annual)$-6,537,000
Net Interest Coverage (TTM)-0.09x
ROA (TTM)-695.19%
EV / EBITDA (TTM)0.10x
EPS Incl Extra (Annual)$-3.95
Current Ratio (Annual)0.49x
Quick Ratio (Quarterly)0.94x
3-Month Avg Trading Volume0.09M
52-Week Price Return-1.11%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.09
52-Week High$1.45
EPS Excl Extra (Annual)$-3.95
26-Week Price Return-14.79%
Quick Ratio (Annual)0.44x
13-Week Price Return-29.93%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)0.99x
Enterprise Value$14.28M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.25
3-Month Return Std Dev82.89%
Net Income / Employee (TTM)$-10,018,300
ROE (Last FY)2.41%
Net Interest Coverage (Annual)-0.34x
EPS Basic Excl Extra (Annual)$-3.95
Total Debt / Equity (Quarterly)10.28x
EPS Incl Extra (TTM)$-4.16
ROI (TTM)-1.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.80
Price vs S&P 500 (52W)-25.48%
Year-to-Date Return-34.39%
5-Day Price Return-3.77%
EPS Normalized (Annual)$-3.95
ROA (5Y Avg)-1267.96%
Month-to-Date Return-4.63%
EBITD / Share (Annual)$-1.28
EPS Basic Excl Extra (TTM)$-4.16
P/TBV (Quarterly)20.47x
P/B Ratio (Annual)0.69x
Book Value / Share (Annual)$7.80
Price vs S&P 500 (13W)-38.19%
Beta0.56x
Revenue / Share (TTM)$0.00
ROE (TTM)-1.74%
52-Week Low$0.63
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AEONAEON Biopharma, Inc. | — | — | C | $0.72 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a proprietary botulinum toxin complex for treating debilitating medical conditions. The company is initially focusing on neuroscience indications where there is significant unmet medical need. ABP-450 represents AEON's lead therapeutic program aimed at patients with conditions that have limited treatment options.